757885

544449

ANTHEM

img img img img
No Data Available

ANTHEM BIOSCIENCES Share Price Update

As of the latest trading session, ANTHEM BIOSCIENCES share price is currently at ₹686, which is down by ₹-7.20 from its previous closing. Today, the stock has fluctuated between ₹683.95 and ₹695.25. Over the past year, ANTHEM BIOSCIENCES has achieved a return of -5.08%. In the last month alone, the return has been 12.41%.

ANTHEM BIOSCIENCES performance

Today’s low

Today’s high

₹ 683.95 ₹ 695.25
₹ 686.45

52 week low

52 week high

₹ 579.15 ₹ 873.50
₹ 686.45

Open Price

₹ 693.20

Prev. Close

₹ 693.20

Volume (Shares)

78664.00

Total traded value

₹ 539.98

Upper Circuit

₹ 831.80

Lower Circuit

₹ 554.60

info

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

ANTHEM BIOSCIENCES fundamentals


  • Market cap (Cr)

    38,558.80

  • P/E Ratio (TTM)

    66.95

  • Beta

    1.26

  • Book Value / share

    50.80

  • Return on equity

    22.98%

  • EPS (TTM)

    10.68

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    112.12

info icon alternate text
  • Market cap (Cr)

    38,710.50

  • P/E Ratio (TTM)

    66.95

  • Beta

    1.27

  • Book Value / share

    50.80

  • Return on equity

    22.98%

  • EPS (TTM)

    10.68

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    112.12

info icon alternate text

ANTHEM BIOSCIENCES Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2025 (Values in Cr)
Revenue 416.58
Operating Expense 281.40
Net Profit 112.12
Net Profit Margin (%) 26.91
Earnings Per Share (EPS) 2.00
EBITDA 177.99
Effective Tax Rate (%) 25.30
Particulars SEP 2025 (Values in Cr)
Revenue 552.23
Operating Expense 352.72
Net Profit 198.43
Net Profit Margin (%) 35.93
Earnings Per Share (EPS) 3.54
EBITDA 279.45
Effective Tax Rate (%) 21.66
Particulars JUN 2025 (Values in Cr)
Revenue 538.01
Operating Expense 366.80
Net Profit 148.34
Net Profit Margin (%) 27.57
Earnings Per Share (EPS) 2.65
EBITDA 223.16
Effective Tax Rate (%) 25.43
Particulars MAR 2025 (Values in Cr)
Revenue 478.98
Operating Expense 303.96
Net Profit 122.56
Net Profit Margin (%) 25.58
Earnings Per Share (EPS) 2.19
EBITDA 235.93
Effective Tax Rate (%) 42.41
Particulars DEC 2024 (Values in Cr)
Revenue 498.26
Operating Expense 352.70
Net Profit 127.99
Net Profit Margin (%) 25.68
Earnings Per Share (EPS) 2.29
EBITDA 191.19
Effective Tax Rate (%) 24.66
Particulars MAR 2025 (Values in Cr)
Revenue 1840.65
Operating Expense 1238.66
Net Profit 506.19
Net Profit Margin (%) 27.50
Earnings Per Share (EPS) 9.05
EBITDA 798.45
Effective Tax Rate (%) 28.84
Particulars MAR 2024 (Values in Cr)
Revenue 1417.54
Operating Expense 1003.28
Net Profit 374.78
Net Profit Margin (%) 26.43
Earnings Per Share (EPS) 6.61
EBITDA 575.40
Effective Tax Rate (%) 22.68
Particulars MAR 2025 (Values in Cr)
Book Value / Share 43.10
ROE % 20.82
ROCE % 28.24
Total Debt to Total Equity 0.08
EBITDA Margin 41.03
Particulars MAR 2024 (Values in Cr)
Book Value / Share 34.43
ROE % 20.04
ROCE % 23.98
Total Debt to Total Equity 0.10
EBITDA Margin 40.07
Particulars MAR 2023 (Values in Cr)
Book Value / Share 30.51
ROE % 22.25
ROCE % 27.36
Total Debt to Total Equity 0.05
EBITDA Margin 48.81
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1543.93
ROE % 39.44
ROCE % 49.35
Total Debt to Total Equity 0.07
EBITDA Margin 49.87
Particulars MAR 2021 (Values in Cr)
Book Value / Share 826.75
ROE % 48.30
ROCE % 53.40
Total Debt to Total Equity 0.23
EBITDA Margin 40.33
Particulars MAR 2025 (Values in Cr)
Book Value / Share 44.24
ROE % 22.98
ROCE % 30.46
Total Debt to Total Equity 0.06
EBITDA Margin 43.39
Particulars MAR 2024 (Values in Cr)
Book Value / Share 34.58
ROE % 20.40
ROCE % 24.74
Total Debt to Total Equity 0.08
EBITDA Margin 40.60
Particulars MAR 2023 (Values in Cr)
Book Value / Share 30.53
ROE % 22.27
ROCE % 27.47
Total Debt to Total Equity 0.05
EBITDA Margin 48.86
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1544.46
ROE % 39.48
ROCE % 49.38
Total Debt to Total Equity 0.07
EBITDA Margin 49.90
Particulars MAR 2021 (Values in Cr)
Book Value / Share 826.76
ROE % 48.30
ROCE % 53.40
Total Debt to Total Equity 0.23
EBITDA Margin 40.33
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 316.98
Total Assets 2807.58
Total Liabilities 2807.58
Total Equity 2409.86
Share Outstanding 55
Price to Book Ratio 0.00
Return on Assets (%) 16.07
Return on Capital (%) 17.92
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 184.35
Total Assets 2398.11
Total Liabilities 2398.11
Total Equity 1924.65
Share Outstanding 55
Price to Book Ratio 0.00
Return on Assets (%) 15.31
Return on Capital (%) 17.03
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 342.84
Total Assets 2014.45
Total Liabilities 2014.45
Total Equity 1740.66
Share Outstanding 57
Price to Book Ratio 0.00
Return on Assets (%) 19.12
Return on Capital (%) 20.65
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 348.90
Total Assets 1618.86
Total Liabilities 1618.86
Total Equity 1354.99
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 25.05
Return on Capital (%) 29.17
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 40.76
Total Assets 1033.82
Total Liabilities 1033.82
Total Equity 701.46
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 26.24
Return on Capital (%) 33.85
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 310.95
Total Assets 2835.56
Total Liabilities 2835.56
Total Equity 2473.21
Share Outstanding 55
Price to Book Ratio 0.00
Return on Assets (%) 17.85
Return on Capital (%) 19.6
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 183.84
Total Assets 2324.22
Total Liabilities 2324.22
Total Equity 1933.07
Share Outstanding 55
Price to Book Ratio 0.00
Return on Assets (%) 16.12
Return on Capital (%) 17.85
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 342.79
Total Assets 1993.01
Total Liabilities 1993.01
Total Equity 1741.61
Share Outstanding 57
Price to Book Ratio 0.00
Return on Assets (%) 19.35
Return on Capital (%) 20.78
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 348.86
Total Assets 1619.17
Total Liabilities 1619.17
Total Equity 1355.46
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 25.07
Return on Capital (%) 29.19
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 40.62
Total Assets 1033.73
Total Liabilities 1033.73
Total Equity 701.47
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 26.24
Return on Capital (%) 33.85
Particulars MAR 2025 (Values in Cr)
Net Income 656.86
Cash from Operations 577.33
Cash from Investing -152.11
Cash from Financing -133.60
Net change in Cash 132.62
Free Cash Flow 891.86
Particulars MAR 2024 (Values in Cr)
Net Income 477.31
Cash from Operations 260.15
Cash from Investing -221.45
Cash from Financing -77.18
Net change in Cash -158.48
Free Cash Flow 369.57
Particulars MAR 2023 (Values in Cr)
Net Income 497.29
Cash from Operations 420.98
Cash from Investing -376.01
Cash from Financing 63.97
Net change in Cash -6.05
Free Cash Flow 599.66
Particulars MAR 2022 (Values in Cr)
Net Income 546.14
Cash from Operations 455.91
Cash from Investing -205.45
Cash from Financing 180.67
Net change in Cash 308.13
Free Cash Flow 478.29
Particulars MAR 2021 (Values in Cr)
Net Income 365.56
Cash from Operations 348.28
Cash from Investing -196.03
Cash from Financing -63.26
Net change in Cash 18.33
Free Cash Flow 464.10
Particulars MAR 2025 (Values in Cr)
Net Income 711.42
Cash from Operations 598.83
Cash from Investing -246.31
Cash from Financing -66.42
Net change in Cash 127.10
Free Cash Flow 823.41
Particulars MAR 2024 (Values in Cr)
Net Income 484.77
Cash from Operations 284.40
Cash from Investing -191.75
Cash from Financing -131.59
Net change in Cash -158.94
Free Cash Flow 388.25
Particulars MAR 2023 (Values in Cr)
Net Income 497.78
Cash from Operations 433.98
Cash from Investing -377.90
Cash from Financing 52.85
Net change in Cash -6.07
Free Cash Flow 612.66
Particulars MAR 2022 (Values in Cr)
Net Income 546.59
Cash from Operations 456.34
Cash from Investing -205.77
Cash from Financing 180.67
Net change in Cash 308.24
Free Cash Flow 478.73
Particulars MAR 2021 (Values in Cr)
Net Income 365.57
Cash from Operations 348.19
Cash from Investing -196.08
Cash from Financing -63.26
Net change in Cash 18.19
Free Cash Flow 464.01
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.30 11.82 1.41 209.21 23.12 / 47.55
BLISS GVS PHARMA LTD 231.45 22.13 2.16 2448.49 105.05 / 244.05
CIPLA LTD 1343.35 22.82 3.29 108513.22 1283.00 / 1672.20
FERMENTA BIOTECH LIMITED 330.30 10.99 2.48 972.11 219.00 / 399.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.30 26.25 3.80 209.21 23.12 / 47.55
AMRUTAJAN HEALTH LTD 610.75 30.54 5.16 1765.72 548.05 / 789.95
ASTRAZENECA PHARMA IND LT 8921.25 107.21 27.91 22303.13 6501.60 / 10653.05
BLISS GVS PHARMA LTD 231.45 31.53 2.21 2448.49 105.05 / 244.05

ANTHEM BIOSCIENCES shareholding pattern

Holding

16.34%
74.68%
1.36%
7.59%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

ANTHEM BIOSCIENCES Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
686.45 -0.97 redarrow
red-green-graph indicator
13 Bearish
3 Bullish
  • 5 Days 687.60
  • 26 Days 649.60
  • 10 Days 672.30
  • 50 Days 651.80
  • 12 Days 667.00
  • 100 Days 685.30
  • 20 Days 653.80
  • 200 Days 715.70
691.83 PIVOT

First Support

686.37

First Resistance

698.67

Second Support

679.53

Second Resistance

704.13

Third Support

674.07

Third Resistance

710.97

RSI

66.56

ADX

32.59

MACD

17.34

Williams % R

-9.81

Commodity Channel Index (CCI)

101.76

Date

2026-02-17

Week

145592.00

Same Day

71725.00

Month

134918.00

1 Year

1.27

3 Year

1.27

Over 1 Month

12.41%

down

Over 1 Year

-5.08%

down

Over 3 Months

4.17%

down

Over 3 Years

0.00%

down

Over 6 Months

-13.42%

down

Over 5 Years

0.00%

down

ANTHEM BIOSCIENCES Corporate Actions

Top Gainers

ANTHEM BIOSCIENCES Share Price

Anthem Biosciences Limited was originally incorporated as 'Anthem Biosciences Private Limited', dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to 'Anthem Biosciences Limited' and a Certificate of Incorporation was issued by RoC on December 10, 2024.

The Company has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are high-value products used in drug, agrochemical and speciality chemicals industries.

The Company started operations at Unit I and set up a Custom Synthesis Plant with a capacity of 6 KL in year 2007. It commenced discovery biology services with a fermentation capacity of 2 KL in 2008. It expanded the Custom Synthesis Plant at Unit I increasing its capacity from 6 KL to 24 KL in 2010. It set up a high potent lab at Unit I - Bommasandra Facility in 2016. The Company was merged with Anthem Cellutions (India) Private Limited by acquiring 100% of its share capital in November, 2017. It set up a flow chemistry lab scale and solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1. It commenced operations of the Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL in 2018-19. In year 2020, Company started operations to biological unit 2 earmarked for a specific client. It expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL. In FY 2024, Company set up a wholly owned subsidiary Neoanthem Lifesciences Private Limited and commenced operations at Unit III for development in projects.

Company launched the initial public offering of 59,575,319 equity shares of face value of Rs 2 each by raising funds through offer for sale aggregating to Rs 3395 Crore in July, 2025.

The Company expanded the fermentation capacity to 140 KL at the Unit II in 2025.

Parent organization Indian Private
NSE symbol ANTHEM
Founded 2006
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Anthem Biosciences Ltd?

Answer Field

Anthem Biosciences Ltd share price is for NSE ₹ 686.00 & for BSE ₹ 689.15 as on Feb 18 2026 03:29 PM.

What is the Market Cap of Anthem Biosciences Ltd Share?

Answer Field

The market cap of Anthem Biosciences Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Feb 18 2026 03:29 PM.

What is the 52 Week High and Low of Anthem Biosciences Ltd?

Answer Field

The 52 Week High and Low of Anthem Biosciences Ltd for NSE is ₹ 873.50 and ₹ 579.15 and for BSE is ₹ 873.25 and ₹ 579.45.

What is 1 year return for Anthem Biosciences Ltd?

Answer Field

The 1 year returns on the stock has been -5.08%.

What is the P/E Ratio of Anthem Biosciences Ltd Share?

Answer Field

As on Feb 18 2026 03:29 PM the price-to-earnings (PE) ratio for Anthem Biosciences Ltd share is 66.95.

What is the PB ratio of Anthem Biosciences Ltd Share?

Answer Field

As on Feb 18 2026 03:29 PM, the price-to-book (PB) ratio for Anthem Biosciences Ltd share is 50.80.

How to Buy Anthem Biosciences Ltd Share?

Answer Field

You can trade in Anthem Biosciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Anthem Biosciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Anthem Biosciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Anthem Biosciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59